Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings GlaxoSmithKline plc: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
Highlights: GlaxoSmithKline plc
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: GlaxoSmithKline plc
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company is in debt and has limited leeway for investment
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

GlaxoSmithKline plc SectorUnited Kingdom

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

GlaxoSmithKline plc SectorUnited Kingdom

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

GlaxoSmithKline plc SectorUnited Kingdom

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

GlaxoSmithKline plc SectorUnited Kingdom

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

GlaxoSmithKline plc SectorUnited Kingdom

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
10TCr -
1,01300Cr
A
64TCr -
BBB
- -
46TCr
AAA
-
35TCr
AA
26TCr
AAA
25TCr
A
20TCr
A
19TCr
BBB
18TCr
AA
Average 36.64TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. GSK Stock
  4. GSK Stock
  5. Ratings GlaxoSmithKline plc
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!